Eleventh-Hour Skeptics Target Sinking Clovis Oncology, Inc. (CLVS)

Piper Jaffray downgraded Clovis Oncology Inc (NASDAQ:CLVS), sending the shares sliding in intraday action

May 15, 2015 at 12:00 PM
facebook twitter linkedin

Clovis Oncology Inc (NASDAQ:CLVS) has taken a turn for the worse today -- off 6.4% at $93.99 -- after Piper Jaffray downgraded the stock to "neutral" from "overweight," explaining a "point of maximal optimism may have been reached for the [company's] clinical data." Put players have been quick to respond to the sell-off, with the contracts changing hands at seven times the average intraday pace.

Receiving notable attention is the stock's May 90 put, which is being bought to open for a volume-weighted average price (VWAP) of $0.35. Based on this average entry price, breakeven for the put buyers at tonight's close -- when front-month options expire -- is $89.65 (strike less VWAP). Earlier, CLVS hit an intraday low of $91.18.

Today's accelerated put volume is nothing new for CLVS. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the equity's 50-day put/call volume ratio of 0.55 ranks higher than 77% of all similar readings taken in the past year.

Echoing this is the security's Schaeffer's put/call open interest ratio (SOIR) of 0.93, which arrives in the 72nd percentile of its annual range. In other words, short-term speculators are more put-heavy than usual toward CLVS.

Heading into today's session, Clovis Oncology Inc (NASDAQ:CLVS) was boasting a 79.3% year-to-date lead. Part of this impressive price action was as a result of a regulatory boost in mid-April, as well as yesterday's 16.7% pop -- which came after the company said it will present data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting later this month.

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!